India, March 12 -- Pfizer Inc. (PFE) announced Tuesday that its Phase 3 study of the antibody-drug conjugate ADCETRIS (brentuximab vedotin) in combination with lenalidomide and rituximab showed positive overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma or DLBCL.
DLBCL is the most common type of lymphoma and is a fast-growing, aggressive blood cancer. Pfizer's ADCETRIS is a standard of care for patients with certain lymphomas and is approved for seven indications in the U.S.
ECHELON-3 is an ongoing, randomized, double-blind, multicenter Phase 3 study evaluating ADCETRIS plus lenalidomide and rituximab versus lenalidomide and rituximab plus placebo in adult patients with relapsed/refractory DLBCL, regardles...